An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Recruiting in Palo Alto (17 mi)
+3 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Target PharmaSolutions, Inc.
No Placebo Group
Approved in 2 jurisdictions
Trial Summary
What is the purpose of this trial?The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.
Eligibility Criteria
Participant Groups
1Treatment groups
Experimental Treatment
Group I: tenofovir alafenamideExperimental Treatment0 Interventions
Patients with a medication history of tenofovir alafenamide (TAF).
Tenofovir Alafenamide (TAF) is already approved in United States, European Union for the following indications:
🇺🇸 Approved in United States as Vemlidy for:
- Chronic hepatitis B virus (HBV) infection
- HIV-1 infection
🇪🇺 Approved in European Union as Vemlidy for:
- Chronic hepatitis B virus (HBV) infection
- HIV-1 infection
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
UHN Toronto General HospitalToronto, Canada
University of MichiganAnn Arbor, MI
Stanford UniversityRedwood City, CA
Asian Pacific Liver Center at Coalition of Inclusive MedicineLos Angeles, CA
Loading ...
Who is running the clinical trial?
Target PharmaSolutions, Inc.Lead Sponsor